In conclusion, first-line EGFR-TKIs treatment was generally associated with similar survival outcomes in advanced EGFR-mutant NSCLC patients with common and uncommon mutations, except that it seemed less effective treating and preventing BMs in patients harboring uncommon mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.